Chondroxide - instructions for use, dose, side effects, contraindications

Excipients: calcium stearate - 4.8 mg, crospovidone - 12.39 mg, povidone-KZO - 9.312 mg, microcrystalline cellulose - 96.0 mg, magnesium hydroxycarbonate pentahydrate-107,498 mg.

Description:

Tablets from white to white with a yellowish or kremovatym shade of color, are allowed blotches, with a risk and a facet.

Pharmacotherapeutic group:Reparation of tissue stimulator of natural origin.

ATX: & nbsp

M.01.A.X.25 Chondroitin sulfate

Pharmacodynamics:Has chondro-stimulating, regenerating, anti-inflammatory action. Chondroxide ® participates in the construction of the main substance of cartilage and bone tissue; affects the metabolic processes in the hyaline and fibrous cartilage, inhibits enzymes that cause damage to the cartilaginous tissue. The drug inhibits the processes of destruction of cartilaginous tissue and stimulates the recovery processes in the articular cartilage.

Chondroxide® stimulates the biosynthesis of proteoglycans, promotes the regeneration of the joint bag and the cartilaginous surfaces of the joints, has an anti-inflammatory effect. Slows the resorption of bone tissue and reduces calcium loss, accelerates the recovery of bone tissue.

Chondroxide® slows the progression of osteoarthritis and osteochondrosis. With the use of the drug Chondroxide®, soreness decreases and the mobility of the affected joints improves, while the therapeutic effect persists for a long time after the end of the course of therapy.

Having structural similarity with heparin, it can potentially prevent the formation of fibrin clots in the synovial and subchondral microcirculatory bed.

Pharmacokinetics:

Suction

With a single admission of the medial therapeutic dose, the maximum concentration in the plasma is reached after 3-4 hours, in synovial fluid - after 4-5 hours. Bioavailability of the drug is 13%.

Distribution

Accumulates mainly in the cartilaginous tissue (the maximum concentration in the articular cartilage is reached after 48 hours); the synovial membrane is not an obstacle to its penetration into the joint cavity.

Excretion

CONCLUSIONSkidneys within 24 hours.

Indications:Degenerative and dystrophic diseases of the joints and spine: treatment and prevention of osteoarthrosis, osteochondrosis of the spine.

Contraindications:Hypersensitivity to the components of the drug, children's age (effectiveness and safety of use in children are not established), pregnancy, the period of breastfeeding.

Carefully:Bleeding, a tendency to bleeding.

Dosing and Administration:

Inside, for 0.5 g (2 tablets) 2 times a day.

Tablets are taken with a small amount of water.

The recommended duration of the initial course of treatment is 6 months. The therapeutic effect of the drug persists for 3-5 months after its withdrawal, depending on the location and stage of the disease. If necessary, it is possible to conduct repeated courses of treatment, the duration of which is determined individually.

Side effects:

Frequency estimation: rarely - from> = 0.01% to <0.1%.

Disorders from the gastrointestinal tract: rarely - nausea, vomiting, diarrhea.

Immune system disorders: rarely - allergic reactions.

Overdose:

Symptoms: rarely - nausea, vomiting, diarrhea, with prolonged admission in excessively high doses (more than 3 g / day), hemorrhagic eruptions are possible.

Treatment: symptomatic therapy.

Interaction:It is possible to increase the effect of indirect anticoagulants, antiplatelet agents, fibrinolytic agents.

Special instructions:

When the drug is used together with indirect anticoagulants, antiplatelet agents, fibrinolytic drugs, more frequent monitoring of blood clotting parameters is required. Impact on the ability to drive and machinery Does not affect the ability to drive and other mechanisms.

Form release / dosage:Tablets 250 mg.

Packaging:10 tablets per contour cell pack. 3, 5, 6, 9 or 10 contour mesh packages together with instructions for medical use of the drug are placed in a cardboard pack.

Storage conditions:In dry, dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:

2 years.

Do not use after the expiration date.

Terms of leave from pharmacies:Without recipe

Registration number:LS-002295

Date of registration:15.03.2012

The owner of the registration certificate:NIZHFARM, JSC NIZHFARM, JSC Russia

Manufacturer: & nbsp

NIZHFARM, JSC Russia

Information update date: & nbsp28.09.2015

Illustrated instructions

Instructions

Chondroxide® (Chondroxide®)